linjc16/ctgov huggingface dataset:
Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers

Study Overview
=================
Brief Summary
-----------------
Purpose of the project is to examine the effectiveness of Reinforcement-Based Treatment (RBT) on drug abuse and psychosocial outcomes of iner city opiate abusers who have recently completed a brief detoxification.

Detailed Description
-----------------
Participants are randomized into one of 3-groups: 1) those receiving intensive behavioral therapy plus abstinence-contingent housing, 2) those receiving recovery housing alone, and 3) those receiving standard care (referrals to community providers). For the two groups receiving recovery housing, rent payment is provided for a period of 3 months, as long as the participant remains drug-free.

Official Title
-----------------
Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers

Conditions
-----------------
Drug Abuse

Intervention / Treatment
-----------------
* Behavioral: Reinforcement Based Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: opiate dependent agree to live in recovery housing Exclusion Criteria: acute psychiatric disorder pregnant over 65

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Group 1<br>Standard care following detoxification | |
| Active Comparator: Group 2<br>Recovery housing following detoxification | Behavioral: Reinforcement Based Treatment<br>* 3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment<br>|
| Experimental: Group 3<br>Recovery housing plus counseling | Behavioral: Reinforcement Based Treatment<br>* 3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug abstinence at follow-up |  | 1, 3 and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rates of employment |  | 1, 3, and 6 months |
The Gut and Skin Microbiome in Vitiligo Disease Progression

Study Overview
=================
Brief Summary
-----------------
Investigators plan to perform a pilot study that aims to characterize the microbiome of human vitiligo patients with both active and stable disease and compare this to the microbiome of age and sex matched controls. The investigators aim to answer the question whether the gut and skin microbiome of patients with vitiligo differs from the general population.

Official Title
-----------------
The Gut and Skin Microbiome in Vitiligo Disease Progression

Conditions
-----------------
Vitiligo, Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with and/or without vitiligo lesional expansion over the past year. Age/sex-matched controls who do not have a diagnosis of vitiligo Subjects who are age 18-89 years of age at time of enrollment Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443) Exclusion Criteria: Subjects who are younger than 18 years of age or 90 years of age or older Subjects who are unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults with vitiligo<br> | |
| Healthy adults<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbiome composition | Diversity analysis of microbiome samples in control subjects versus vitiligo subjects (measured by number of bacteria species/sample) | 12 months | 
| Disease Progression | Disease progression in control subjects versus vitiligo subjects (measured by VASI score (0-100)). | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diet History Food Frequencies | Scoring from diet history food frequency questionnaires (measured by average daily food frequency scores). | 12 months |
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

Study Overview
=================
Brief Summary
-----------------
In this study PEAR1 polymorphisms effects will be analyze in blood platelets to determine how PEAR1 regulates platelet activation.

Detailed Description
-----------------
Several large-scale studies have confirmed the long held notion that platelet responses to different agonists are highly variable, within well defined populations of healthy donors. Single nucleotide polymorphisms in genes encoding platelet proteins can explain the wide range of responses to standard platelet agonists. Yet, numerous SNPs point towards proteins with previously unknown function in platelets, wich modulate the complex network of signaling events that regulate platelet function and further augment variability. PEAR1 is mainly expressed in platelets and endothelial cells. A few studies have linked SNPs in PEAR1 with decreased or increased platelet responses to various agonists. However, hitherto, no direct functional studies have been carried out to determine whether and how PEAR1 modulate intracellular signaling pathways relevant for platelet function.

Official Title
-----------------
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

Conditions
-----------------
Platelet Function

Intervention / Treatment
-----------------
* Other: blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy voluntary donors Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: peripheral blood<br>healthy voluntary donors | Other: blood test<br>* preparation of blood platelets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PEAR1 gene, whether and how PEAR 1 modulate intracellular signaling pathways relevant for platelet function
Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare anaesthesia (for back surgery) using endotracheal intubation (patients anaesthized in the supine position)with anaesthesia using a laryngeal mask (anaesthesia induced and the laryngeal mask placed with the patient in the prone position on the operation table) as regards advantages, adverse effects and time spent. The anaesthesia in the 2 groups of patients is identical (propofol, remifentanil, rocuronium). Two groups of 70 pt. each are included in the stud. The inclusion criterias are patients 18-70 yrs., ASA group 1-2, normal airways, patients scheduled for back surgery with an estimated duration of less than 2 hours. Adverse effects (related to the placement on the operation table i.e. pain in the arms or shoulders, pain in the throat, blood in the sputum, irritation in the eyes etc.) and time spent with all the procedures (anaesthesia, placement of the airway, surgery and emergence from the anaesthesia are registered. The hypothesis is that the method using the laryngeal mask is faster and with fewer adverse effects.

Official Title
-----------------
Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position. Advantages, Adverse Effects and Time Consumation for the Two Methods.

Conditions
-----------------
Anaesthesia, Adverse Effects

Intervention / Treatment
-----------------
* Device: laryngeal mask
* Device: endotracheal tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for backsurgery of an espected duration less than 2 hours, Age 18-70 years, ASA (american society of anaaesthesiology) class 1-2, Normal airways Exclusion Criteria: Body mass index >35 Expected time of surgery > 2 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Endotracheal group<br>airway management: endotracheal tube | Device: endotracheal tube<br>* Unomedical endotracheal tube<br>|
| Active Comparator: laryngeal mask group<br>airway management: laryngeal mask | Device: laryngeal mask<br>* LMA Proseal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time of anaesthesia |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse effects using the 2 methods |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anaesthesia, laryngeal mask, prone position
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers

Study Overview
=================
Brief Summary
-----------------
A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke

Detailed Description
-----------------
Subjects will orally self-administer 2 study products, each in the form of a dissolvable lozenge, and will complete questionnaires on demographics, urges to smoke, and product rating.

Official Title
-----------------
A Randomized, Double-Blind, Active-Controlled, Crossover, Pilot Study to Evaluate the Safety and Efficacy of CigRx™ Lozenge, a Non-Nicotine Non-Tobacco Dietary Supplement, in Daily Smokers in Temporarily Reducing the Desire to Smoke

Conditions
-----------------
Smoking, Tobacco Use Disorder

Intervention / Treatment
-----------------
* Dietary Supplement: CigRx Lozenge
* Other: Tobacco Lozenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult smokers Smoking for at least 5 years Smoking at least one (1) pack of cigarettes a day Exclusion Criteria: Allergy to lozenge components

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 72 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CigRx Lozenge<br>CigRx Lozenge | Dietary Supplement: CigRx Lozenge<br>* lozenge made of dietary supplements<br>|
| Active Comparator: Tobacco Lozenge<br>Tobacco Lozenge | Other: Tobacco Lozenge<br>* lozenge made of compressed cured tobacco extract<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect on subject's craving to smoke | craving is assessed by changes in questionnaire answers over time | 4 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of information on adverse events related to study products |  | 5 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dietary supplement, nutraceutical
One Lung Ventilation

Study Overview
=================
Brief Summary
-----------------
Specific Aims: 1) Measure exhalation enthalpy in patients receiving conventional positive pressure ventilation during stable hemodynamic conditions. 2) Measure exhalation enthalpy in patients following change from two-lung ventilation to one-lung ventilation while minute ventilation remains constant.

Official Title
-----------------
Effect of One-Lung Ventilation on Respiratory Gas Heat Content

Conditions
-----------------
Evaluate the Changes in Respiratory Heat Content During One Lung Ventilation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled for elective surgical procedures requiring one lung ventilation. Exclusion Criteria: Age <18 years. Pregnancy. Prisoners. Planned pneumoperitoneum.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of One-Lung Ventilation on Respiratory Gas Heat Content | Changes in respiratory heat content during one-lung ventilation. | One year. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory enthalpy, One Lung Ventilation
Protein Classifier for Thyroid Indeterminate Nodules

Study Overview
=================
Brief Summary
-----------------
In multi-center, prospective, double-blind cohorts, PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules.

Official Title
-----------------
Protein Classifier for Thyroid Indeterminate Nodules： a Multi-center Prospective Clinical Study

Conditions
-----------------
Thyroid Nodule

Intervention / Treatment
-----------------
* Diagnostic Test: PCT-DIA/MS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with aged 18 to 70 years old; Patients with thyroid nodules who have not been treated with drugs; Patients who were diagnosed as Bethesda III and IV by cytology and pathology before operation; Patients who underwent total / partial thyroidectomy and had histopathological reports of corresponding cellular pathological punctured nodules; Patients voluntarily participate in the study after informed consent. Exclusion Criteria: Patients without operation; Patients with insufficient FNA sample size (judged by the laboratory).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PCT-DIA/MS<br>PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules | Diagnostic Test: PCT-DIA/MS<br>* PCT-DIA/MS will be validated to classify FNA biopsy specimens<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| protein classifier | classify thyroid indeterminate nodules as Benign or Malignant | immediately after the procedure |
Evaluation of a Probiotic On Anxiety and Stress in Healthy Adults Sensible to Daily Stress

Study Overview
=================
Brief Summary
-----------------
The purpose of the the study is to determine if PROBIOSTICK® decrease stress and anxiety of people sensible to daily stress.

Official Title
-----------------
Evaluation Des Effets Anti-Stress D'un Probiotique Nomme PROBIOSTICK® Sur Des Sujets Humains Volontaires Sains Sensibles Au Stress De La Vie Quotidienne

Conditions
-----------------
Anxiety, Stress

Intervention / Treatment
-----------------
* Dietary Supplement: PROBIOSTICK® during 30 days
* Dietary Supplement: Placebo during 30 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasian healthy men or women Age 30-60 years Hospital anxiety and depression score equal or below 12 and above 4 Standard safety biology Exclusion Criteria: HAD A results above 12 and below 4 HAD D results above 12 Neurologic or psychiatric pathology Consumption of psychotropic High level of caffeine consumption Any important chronic pathology Drugs wich impairs concentration, anxiety and stress

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 2<br>Every morning subjects will consume a stick of placebo during 30 days | Dietary Supplement: Placebo during 30 days<br>* Every morning subjects will consume a stick of placebo during 30 days<br>|
| Experimental: 1<br>Every morning subjects will consume a stick of PROBIOSTICK® during 30 days | Dietary Supplement: PROBIOSTICK® during 30 days<br>* Every morning subjects will consume a stick of PROBIOSTICK® during 30 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SCL 90 questionnaire |  | day 0 and day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stress perçu, coping de vitaliano, hospital anxiety and depression questionnaires and urinary cortisol measurement |  | day-14 ; day 0 and day 30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PROBIOSTICK®, Probiotic, Anxiety, Daily stress
Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

Study Overview
=================
Brief Summary
-----------------
A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Detailed Description
-----------------
A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using mathematical epidemic models, the study will assess levels of existing and scaled-up interventions necessary for HCV elimination from PLWH in San Diego.

Official Title
-----------------
Impact of Direct Acting Antivirals Uptake in Controlling Hepatitis C Epidemic and Modeling Interventions for Hepatitis C Elimination Among HIV-infected Persons in San Diego

Conditions
-----------------
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody Exclusion Criteria: With no history of or current HCV infection defined as having a negative HCV antibody from 2008 to 2020

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective<br> | |
| Prospective<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Annual proportion of HIV-infected patients who initiate direct acting antivirals |  | 2014-2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Annual proportion of PLWH co-infected with HCV who are treatment naïve, previously treated with no sustained virologic response (SVR), or re-infected post-SVR |  | 2008-2020 | 
| Annual HCV chronic prevalence, primary incidence, and reinfection incidence among HIV-infected patients |  | 2008-2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Hepatitis C, Direct acting antivirals, Hepatitis C modeling